| Dr Joshua S Hooper, OD | |
|
1327 Troup Hwy, Tyler, TX 75701-4443 | |
| (903) 531-4733 | |
| Not Available |
| Full Name | Dr Joshua S Hooper |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 20 Years |
| Location | 1327 Troup Hwy, Tyler, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154328870 | NPI | - | NPPES |
| 925395 | Other | TX | WEB-TPA |
| 0038FF | Other | TX | TEXAS COMMUNITY CARE |
| 0038FF | Other | TX | TEXAS TRUE CHOICE |
| 11450424 | Other | TX | AETNA TRS CARE |
| 202043539 | Other | TX | TRICARE SOUTH |
| 5451470001 | Other | TX | STERLING OPTION I |
| 0038FF | Other | TX | HEALTHFIRST TPA |
| 11450424 | Other | TX | AETNA |
| 81256Q | Other | TX | BLUE CROSS BLUE SHIELD GOVERNMENT |
| 0038FF | Other | TX | SUPERIOR VISION |
| 5451470001 | Other | TX | CIGNA GOVERNMENT SERVICES |
| 921841 | Other | TX | BLOCK VISION |
| 9370971 | Other | TX | PHCS |
| 0038FF | Other | TX | UNITED HEALTH CARE |
| 22704 | Other | TX | NATIONAL VISION ADMINISTRATORS |
| 170498302 | Medicaid | TX | |
| 22704 | Other | TX | ALWAYS VISION |
| 5451470001 | Other | TX | STERLING OPTION II |
| 0038FF | Other | TX | VISION SERVICE PLAN |
| 0038FF | Other | TX | PRINICIPAL FINANCIAL GROUP |
| 0038FF | Other | TX | GROUP & PENSION ADMINISTRATORS |
| 170498303 | Medicaid | TX | |
| TIN PLUS 021 | Other | TX | TRICARE |
| 0038FF | Other | TX | VISION CARE PLAN |
| 60583 | Other | TX | SAFEGUARD |
| 81256Q | Other | TX | BLUE CROSS BLUE SHIELD |
| 82840Q | Other | TX | BCBS |
| 9370971 | Other | TX | BENEFIT PLANNERS |
| HO96271 | Other | TX | INEGRATED HEALTH PLAN |
| TIN PLUS 015 | Other | TX | TRICARE TC EYE JV LOCATION |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 6589TG (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Longview Eye Associates Pa | 5294832986 | 7 |
| Ward Eye Associates Pc | 7911308283 | 6 |
News Archive
Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.
Dune Medical Devices, Inc., announced today that it has received an Approvable Letter for its Premarket Approval Application (PMA) from the Food and Drug Administration. The Approvable Letter states that the MarginProbe System PMA is approvable subject to final agreement with FDA on the design of the required Post Approval Study.
Nearly half of all birth defects involve the face and skull and, for the most part, scientists remain unclear as to why most occur. To better serve families at risk for these conditions, scientists need a comprehensive and systematic understanding of how the faces of healthy children form and what goes wrong to cause common malformations, such as cleft lip and palate.
Researchers at Huntsman Cancer Institute at the University of Utah (U of U) presented the first outcomes evaluation of an adult oncology hospital-at-home program today at the 2020 American Society of Clinical Oncology annual meeting.
› Verified 1 days ago
| Provider Name | Tyler Eye Care, P.a. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1861615254 PECOS PAC ID: 2567450653 Enrollment ID: O20040505001721 |
News Archive
Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.
Dune Medical Devices, Inc., announced today that it has received an Approvable Letter for its Premarket Approval Application (PMA) from the Food and Drug Administration. The Approvable Letter states that the MarginProbe System PMA is approvable subject to final agreement with FDA on the design of the required Post Approval Study.
Nearly half of all birth defects involve the face and skull and, for the most part, scientists remain unclear as to why most occur. To better serve families at risk for these conditions, scientists need a comprehensive and systematic understanding of how the faces of healthy children form and what goes wrong to cause common malformations, such as cleft lip and palate.
Researchers at Huntsman Cancer Institute at the University of Utah (U of U) presented the first outcomes evaluation of an adult oncology hospital-at-home program today at the 2020 American Society of Clinical Oncology annual meeting.
› Verified 1 days ago
| Provider Name | Longview Eye Associates Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1790799773 PECOS PAC ID: 5294832986 Enrollment ID: O20070514000547 |
News Archive
Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.
Dune Medical Devices, Inc., announced today that it has received an Approvable Letter for its Premarket Approval Application (PMA) from the Food and Drug Administration. The Approvable Letter states that the MarginProbe System PMA is approvable subject to final agreement with FDA on the design of the required Post Approval Study.
Nearly half of all birth defects involve the face and skull and, for the most part, scientists remain unclear as to why most occur. To better serve families at risk for these conditions, scientists need a comprehensive and systematic understanding of how the faces of healthy children form and what goes wrong to cause common malformations, such as cleft lip and palate.
Researchers at Huntsman Cancer Institute at the University of Utah (U of U) presented the first outcomes evaluation of an adult oncology hospital-at-home program today at the 2020 American Society of Clinical Oncology annual meeting.
› Verified 1 days ago
| Provider Name | Ward Eye Associates Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1184208134 PECOS PAC ID: 7911308283 Enrollment ID: O20210623003523 |
News Archive
Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.
Dune Medical Devices, Inc., announced today that it has received an Approvable Letter for its Premarket Approval Application (PMA) from the Food and Drug Administration. The Approvable Letter states that the MarginProbe System PMA is approvable subject to final agreement with FDA on the design of the required Post Approval Study.
Nearly half of all birth defects involve the face and skull and, for the most part, scientists remain unclear as to why most occur. To better serve families at risk for these conditions, scientists need a comprehensive and systematic understanding of how the faces of healthy children form and what goes wrong to cause common malformations, such as cleft lip and palate.
Researchers at Huntsman Cancer Institute at the University of Utah (U of U) presented the first outcomes evaluation of an adult oncology hospital-at-home program today at the 2020 American Society of Clinical Oncology annual meeting.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joshua S Hooper, OD Po Box 846098, Dallas, TX 75284-6098 Ph: (903) 324-6450 | Dr Joshua S Hooper, OD 1327 Troup Hwy, Tyler, TX 75701-4443 Ph: (903) 531-4733 |
News Archive
Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.
Dune Medical Devices, Inc., announced today that it has received an Approvable Letter for its Premarket Approval Application (PMA) from the Food and Drug Administration. The Approvable Letter states that the MarginProbe System PMA is approvable subject to final agreement with FDA on the design of the required Post Approval Study.
Nearly half of all birth defects involve the face and skull and, for the most part, scientists remain unclear as to why most occur. To better serve families at risk for these conditions, scientists need a comprehensive and systematic understanding of how the faces of healthy children form and what goes wrong to cause common malformations, such as cleft lip and palate.
Researchers at Huntsman Cancer Institute at the University of Utah (U of U) presented the first outcomes evaluation of an adult oncology hospital-at-home program today at the 2020 American Society of Clinical Oncology annual meeting.
› Verified 1 days ago
Bryan E Frazier, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 5791 New Copeland Rd, Tyler, TX 75703 Phone: 903-339-3035 Fax: 903-339-3036 | |
Dr. David Michael Johnson, O.D. Optometrist Medicare: May Accept Medicare Assignments Practice Location: 2756 S Broadway Ave, Tyler, TX 75701 Phone: 903-593-2345 Fax: 903-593-4646 | |
Piney Woods Family Eyecare Optometrist Medicare: Not Enrolled in Medicare Practice Location: 701 W Southwest Loop 323, Tyler, TX 75701 Phone: 480-375-8908 | |
Vision Source Of Tyler Optometrist Medicare: Medicare Enrolled Practice Location: 136 Shelley Drive, Tyler, TX 75701 Phone: 903-561-8686 Fax: 903-581-1518 | |
Dr. Andrew Eric Hamilton, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 4826 S Broadway Ave, Tyler, TX 75703 Phone: 903-581-6995 | |
Dat Ly, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 7924 S Broadway Ave, Ste 200, Tyler, TX 75703 Phone: 903-617-6864 Fax: 903-504-5758 | |
20/20 Icare Tyler Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 4824 S Broadway Ave, Tyler, TX 75703 Phone: 903-581-2020 |